WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

28 July 2017

TiGenix Transparency information ENNL

29 June 2017

TiGenix opens US headquarters in Cambridge, MA (ENNLFRES)

UPCOMING EVENTS

  • INVESTORS AND PARTNERING
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
20.50 USD
Change (%):
0.00 (0.00%)
BRU
0.90 EUR
Change (%):
0.01 (0.56%)